CLINICAL TRIALS PROFILE FOR RIFADIN

All Clinical Trials for Rifadin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00439166 ↗	Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid	Completed	The Physicians' Services Incorporated Foundation	Phase 3	2007-02-01	This study will determine if biomarkers found in the cerebrospinal fluid of people with Alzheimer's disease, are affected by treatment with two common antibiotics, doxycycline and rifampicin, suggesting a disease-modifying effect of those treatments.
NCT00439166 ↗	Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid	Completed	Hamilton Health Sciences Corporation	Phase 3	2007-02-01	This study will determine if biomarkers found in the cerebrospinal fluid of people with Alzheimer's disease, are affected by treatment with two common antibiotics, doxycycline and rifampicin, suggesting a disease-modifying effect of those treatments.
NCT00621309 ↗	Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions	Completed	Fred Hutchinson Cancer Research Center	Phase 1	2008-03-01	Adverse drug-drug interactions (DDIs) are responsible for approximately 3% of all hospitalizations in the US, perhaps costing more than $1.3 billion per year. One of the most common causes of DDIs is the when one drug alters the metabolism of another. A key enzyme in the liver and intestine, called "cytochrome P450 3A4 (CYP3A4) is generally considered to be the most important drug metabolizing enzyme. The gene for CYP3A4 can be 'turned on' by the presence of certain other drugs, resulting in much higher levels of CYP3A4 in the liver and intestine. Thus, when a drug that induces CYP3A4 is given with or before another drug that is metabolized by 3A4, a 'drug-drug' interaction occurs because the first drug (the inducer) greatly changes the rate at which the second drug (CYP3A4 substrate) is removed from the body. Many drugs increase CYP3A4 activity by binding to a receptor called the Pregnane-X-Receptor (PXR), which is a major switch that controls the expression of the CYP3A4 gene. Using human liver cells we have demonstrated that sulforaphane (SFN), found in broccoli, can block drugs from activating the PXR receptor, thereby inhibiting the switch that causes CYP3A4 induction. The purpose of this project is to determine if SFN can be used to block adverse DDIs that occur when drugs bind to and activate the PXR receptor and subsequently induce CYP3A4 activity. We will recruit 24 human volunteers to participate in the study. This project will determine whether SFN can prevent the drug Rifampin from binding to PXR and increasing CYP3A4 activity in humans following oral administration of SFN (broccoli sprout extract). The rate of removal of a small dose of the drug midazolam will be used to determine the enzymatic activity of CYP3A4 before and following treatment with Rifampin, in the presence or absence of SFN, since midazolam is only eliminated from the bloodstream by CYP3A4. . We predict that SFN will prevent the increase in midazolam clearance (metabolism) that normally follows treatment with the antibiotic, rifampicin. This research is important because it could potentially lead to a simple, cost-effective way of preventing one of the most common causes of adverse drug-drug interactions that occurs today. For example, rifampicin, which is a cheap and effective antibiotic used to treat TB, cannot be used in HIV/AIDS patients because it increases the metabolism of many of the antiretroviral drugs used to treat HIV/AIDS. TB is a major opportunistic infection in AIDS patients, so this is a serious clinical problem, especially in developing countries where more expensive alternative drug therapies are not available. We hypothesize that co-formulation of rifampicin with SFN could block this drug-drug interaction without altering its efficacy, thereby allowing its use in HIV/AIDS patients infected with TB. This is but one example of numerous drug-drug interactions that occur via this mechanism.

Clinical Trial Conditions for Rifadin

Condition Name

Condition Name for Rifadin
Intervention	Trials
Healthy	3
Pulmonary Tuberculosis	3
Cystic Fibrosis	2

Condition MeSH

Condition MeSH for Rifadin
Intervention	Trials
Tuberculosis	7
Tuberculosis, Pulmonary	5
Cystic Fibrosis	2

Clinical Trial Locations for Rifadin

Trials by Country

Trials by Country for Rifadin
Location	Trials
United States	65
South Africa	7
Canada	5
India	4
France	3

Trials by US State

Trials by US State for Rifadin
Location	Trials
California	6
Florida	4
Texas	4
Colorado	4
Washington	4

Clinical Trial Progress for Rifadin

Clinical Trial Phase

Clinical Trial Phase for Rifadin
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	5
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Rifadin
Clinical Trial Phase	Trials
Completed	27
Recruiting	4
Unknown status	2

Clinical Trial Sponsors for Rifadin

Sponsor Name

Sponsor Name for Rifadin
Sponsor	Trials
European and Developing Countries Clinical Trials Partnership (EDCTP)	3
University of Washington	3
University of California, San Francisco	3

Sponsor Type

Sponsor Type for Rifadin
Sponsor	Trials
Other	80
Industry	17
NIH	5

RIFADIN (Rifampicin) Clinical Trials, Market Analysis, and Projection

Last updated: February 19, 2026

Rifadin (rifampicin) continues to be a cornerstone therapy for tuberculosis (TB) and is under investigation for additional indications. Its established efficacy and evolving patent landscape necessitate a focused analysis for R&D and investment strategies.

What is the Current Status of Rifadin's Clinical Development?

Rifadin's primary indication remains the treatment of tuberculosis (TB), a multi-drug regimen where it plays a critical role in shortening treatment duration and preventing drug resistance [1]. Beyond TB, ongoing research is exploring its utility in other bacterial infections, though these are less advanced.

Key Clinical Trial Areas:

• Tuberculosis (Active & Latent): Rifampicin is a first-line agent in combination therapies for Mycobacterium tuberculosis [2]. Clinical trials continue to refine optimal dosing, duration, and combinations to combat drug-resistant TB strains (e.g., multidrug-resistant TB [MDR-TB] and extensively drug-resistant TB [XDR-TB]) [3]. Research also focuses on shorter treatment regimens and preventive therapies for latent TB infection [4].
• Other Mycobacterial Infections: Studies evaluate rifampicin's role in treating non-tuberculous mycobacterial (NTM) infections, such as those caused by Mycobacterium avium complex (MAC) and Mycobacterium kansasii, often in combination with other antimicrobials [5].
• Leprosy: Rifampicin is a critical component of multidrug therapy (MDT) for leprosy, recommended by the World Health Organization (WHO) for all forms of the disease [6].
• Prophylaxis: Rifampicin is used for chemoprophylaxis against meningococcal disease and Haemophilus influenzae type b (Hib) infections [7].

Recent Trial Activity Highlights:

• Shortened TB Regimens: Multiple trials, including ACTG 5279 and STRIVE, have investigated shorter rifampicin-containing regimens for TB treatment. While some have shown promise in specific populations, others have encountered challenges related to efficacy or tolerability in complex cases [4].
• Drug-Resistant TB: The development of novel regimens for MDR-TB and XDR-TB often includes rifampicin, though its effectiveness can be compromised by resistance mutations. Trials are exploring higher doses and new combinations to overcome this [3].
• NTM Treatment: Studies are ongoing to determine optimal rifampicin dosages and combinations for specific NTM species and disease manifestations, particularly pulmonary NTM disease [5].

What is Rifadin's Patent Landscape and Exclusivity Status?

The original patents for rifampicin have long expired, making the active pharmaceutical ingredient (API) widely available as a generic. However, patent strategies have shifted towards new formulations, delivery systems, and specific indications.

Key Patent Considerations:

• API Patent Expiry: The core patent for rifampicin expired in the early 1990s [8]. This led to the widespread availability of generic rifampicin products.
• Formulation Patents: Manufacturers have obtained patents for novel formulations designed to improve patient compliance, palatability, or bioavailability. Examples include:
  • Pediatric Formulations: Development of palatable liquid suspensions or dispersible tablets for children, addressing a significant unmet need [9].
  • Modified-Release Formulations: Research into sustained-release or pulsatile-release formulations to optimize dosing intervals and reduce peak-concentration-related side effects [10].
• Combination Therapy Patents: Patents may cover specific combinations of rifampicin with other active agents for treating particular diseases, especially drug-resistant TB or complex NTM infections [11].
• Method of Use Patents: Patents can be granted for new therapeutic uses of rifampicin, even if the drug itself is off-patent. Demonstrating novel efficacy or safety profiles in a specific disease context is crucial for this type of patent [12].
• Manufacturing Process Patents: While less common for established drugs, innovative manufacturing processes that improve purity, yield, or reduce environmental impact can be patented.

Examples of Patent Activity:

• A patent application filed in 2018 by a global pharmaceutical company described a novel pediatric formulation of rifampicin with improved taste masking properties [9].
• Another patent, granted in 2020, covered a combination therapy of rifampicin and a novel oxazolidinone for treating specific strains of MDR-TB [11].
• Patents for fixed-dose combinations (FDCs) of rifampicin with other first-line TB drugs (e.g., isoniazid, pyrazinamide, ethambutol) have been crucial in promoting adherence and simplifying treatment regimens, particularly in resource-limited settings [13].

What is the Market Size and Projection for Rifadin?

The market for rifampicin is substantial, driven primarily by its essential role in tuberculosis treatment globally. While the generic nature of the API limits revenue for basic formulations, demand remains high due to disease prevalence.

Market Segmentation & Drivers:

• Tuberculosis Treatment: This is the largest segment, accounting for the vast majority of rifampicin consumption. The global burden of TB, particularly in low- and middle-income countries (LMICs), ensures consistent demand [14].
• Leprosy Treatment: A smaller but significant market, particularly in endemic regions.
• Other Indications: NTM infections and prophylaxis represent niche markets.
• Key Market Drivers:
  • Global TB incidence and prevalence rates [14].
  • Government procurement programs and public health initiatives for TB control.
  • The WHO's Essential Medicines List, which includes rifampicin [15].
  • The increasing prevalence of drug-resistant TB, necessitating combination therapies.
  • Emergence of new indications or improved formulations that command higher pricing.

Market Size and Growth:

Estimating the precise market size for rifampicin is complex due to the fragmentation of the generic market and the inclusion of rifampicin in various combination products. However, analyses indicate a steady market.

• Global TB Drug Market: The global market for anti-TB drugs was valued at approximately USD 1.5 billion in 2022 and is projected to grow at a CAGR of 3-5% through 2030, driven by efforts to combat the disease and address drug resistance [16]. Rifampicin and its combinations constitute a significant portion of this market.
• Generic API Market: The market for rifampicin API itself is competitive, with pricing influenced by manufacturing costs and supply chain dynamics. Manufacturers focus on volume and efficient production.
• Branded/Specialty Formulations: While less common for rifampicin compared to novel agents, any patented pediatric or novel delivery formulations would likely target a premium segment.

Projection Factors:

• Continued TB Burden: Projections for TB incidence show a slow but persistent global burden, supporting ongoing demand for rifampicin [14].
• Drug Resistance: The rise of MDR-TB and XDR-TB will sustain the need for rifampicin in complex treatment regimens, potentially driving demand for higher-quality or specialized formulations.
• Public Health Investment: Global and national investments in TB control programs are critical drivers of demand, particularly in LMICs.
• Competition: Intense competition within the generic market for rifampicin API and standard formulations will continue to pressure prices.
• Emerging Indications: Successful development of rifampicin for new indications, if achieved, could open new market segments, though this remains a secondary driver compared to TB.

What are the Competitive Dynamics and Key Players?

The rifampicin market is characterized by a dual structure: a highly competitive generic API and finished-dose generic market, and potential niche opportunities for patented formulations or combinations.

Key Player Categories:

• Generic API Manufacturers: A large number of manufacturers worldwide produce rifampicin API, primarily located in India and China, due to cost advantages. Key players include:
  • Lupin Limited
  • Divi's Laboratories
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries
  • Cipla Limited
• Generic Finished-Dose Manufacturers: Companies producing generic tablets, capsules, and suspensions for major markets. These include many of the API manufacturers as well as other pharmaceutical companies. Examples:
  • Teva Pharmaceutical Industries
  • Mylan N.V. (now part of Viatris)
  • Sanofi (historically through Aventis)
• Branded/Specialty Companies: Companies holding patents for novel formulations or specific combination therapies. These are fewer and focus on differentiated products.
• Global Health Organizations & NGOs: Entities like the WHO, Global Fund, and NGOs play a crucial role in procurement, distribution, and ensuring access to rifampicin, especially in high-burden countries.

Competitive Landscape:

• Price Sensitivity: The market for standard rifampicin formulations is highly price-sensitive, driven by tenders from governments and procurement agencies.
• Quality and Regulatory Compliance: Manufacturers must adhere to stringent regulatory standards (e.g., FDA, EMA, WHO Prequalification) to supply to major markets and international organizations.
• Supply Chain Reliability: Consistent and reliable supply is a key differentiator, especially for essential medicines.
• Innovation in Formulations: Companies that can successfully develop and patent improved formulations (e.g., pediatric, taste-masked, easier-to-administer) can achieve premium pricing and market differentiation, albeit in smaller market segments.
• Combination Therapies: Fixed-dose combinations (FDCs) of rifampicin with other anti-TB drugs are widely adopted and represent a significant portion of the market, reducing pill burden and improving adherence.

What are the Key Risks and Opportunities?

The market and R&D landscape for rifampicin presents both significant risks and notable opportunities for stakeholders.

Risks:

• Drug Resistance Evolution: The emergence of rifampicin-resistant M. tuberculosis strains, while leading to the use of alternative agents, could also necessitate more complex and expensive combination regimens where rifampicin's role might be diminished or altered.
• Intense Generic Competition: For standard formulations, price erosion due to a crowded generic market is a primary risk, limiting profitability for API and finished-dose manufacturers.
• Regulatory Hurdles for New Formulations: Obtaining regulatory approval for novel formulations can be time-consuming and costly, with no guarantee of success.
• Supply Chain Disruptions: Global supply chain vulnerabilities, geopolitical events, or raw material shortages can impact production and availability.
• Limited Pipeline for New Indications: While research continues, the discovery of entirely new, broad indications for rifampicin is unlikely, limiting major growth beyond its established uses.
• Adverse Event Profile: Rifampicin is known for drug-drug interactions and can cause side effects like hepatotoxicity and orange discoloration of body fluids, which can limit its use in certain patient populations or when co-administered with other medications.

Opportunities:

• Addressing Unmet Needs in Pediatric TB: Developing palatable, accurately dosed pediatric formulations remains a significant unmet need and a valuable market opportunity.
• Improving Adherence for Drug-Resistant TB: Innovations in drug delivery or fixed-dose combinations that simplify complex MDR-TB regimens can provide a competitive advantage.
• Supply Chain Optimization: For API manufacturers, investing in efficient, high-yield manufacturing processes and robust supply chain management can ensure consistent supply and cost competitiveness.
• Securing Long-Term Contracts: For established players, securing long-term supply agreements with public health organizations and governments provides revenue stability.
• Leveraging Existing Infrastructure for Niche Applications: Companies with rifampicin manufacturing capabilities could explore its use in treating other less common mycobacterial infections or for prophylaxis in specific high-risk settings, provided a clear clinical and economic case exists.
• Combination Therapy Development: Developing novel, patent-protected combination therapies for specific resistant strains or complex NTM infections could offer higher margins and market differentiation.

Key Takeaways

Rifadin (rifampicin) maintains its critical role in tuberculosis and leprosy treatment. The market is dominated by generic competition for the active pharmaceutical ingredient and standard finished-dose products, driven by global TB incidence. Patent strategies have shifted to novel formulations, particularly pediatric versions, and specific combination therapies for drug-resistant strains. While the overall market growth is moderate, opportunities exist for companies focusing on quality, supply chain reliability, and differentiated formulations that address specific patient needs and combat drug resistance. The primary risks revolve around intense price pressure and the evolving landscape of bacterial resistance.

Frequently Asked Questions

1. What is the most significant unmet need in rifampicin therapy currently being addressed? The most significant unmet need is the development of palatable and accurately dosed pediatric formulations of rifampicin for the treatment of tuberculosis in children.

2. How is drug resistance impacting the use of rifampicin? Rifampicin resistance is a growing concern in tuberculosis. While it remains a first-line drug, resistance necessitates the use of alternative, often more toxic and expensive, drug regimens, particularly for multidrug-resistant tuberculosis (MDR-TB).

3. Are there any significant new indications for rifampicin currently in late-stage clinical trials? While rifampicin is being explored for other bacterial infections, there are no major new indications in late-stage clinical trials poised to significantly alter its primary market landscape beyond its established roles in TB, leprosy, and prophylaxis.

4. What is the typical duration of patent protection for new rifampicin formulations? New formulations can receive up to 20 years of patent protection from the filing date, with potential for extensions based on regulatory review periods. However, the market exclusivity for the drug itself is limited by the expiry of the original API patent.

5. How does rifampicin's interaction with other drugs affect its market potential? Rifampicin is a potent inducer of cytochrome P450 enzymes, leading to numerous drug-drug interactions. This necessitates careful management of concomitant medications and can limit its use in patients on certain therapies, impacting prescribing patterns and market access in specific patient subgroups.

---

Citations

[1] World Health Organization. (2020). Tuberculosis treatment guidelines. WHO.

[2] National Institute of Allergy and Infectious Diseases. (n.d.). Tuberculosis (TB). National Institutes of Health. Retrieved from https://www.niaid.nih.gov/diseases-conditions/tuberculosis-tb

[3] Pontali, E., Ippolito, G., & Nienhaus, A. (2017). Treatment of multidrug-resistant tuberculosis. Clinical Infectious Diseases, 64(suppl_1), S43-S47.

[4] Gillespie, S. H., &gence, E. D. (2017). Shortening tuberculosis treatment: the challenge and the opportunity. The Lancet Infectious Diseases, 17(7), 699-707.

[5] Daley, C. L., & Young, A. C. (2017). Treatment of nontuberculous mycobacterial pulmonary disease. Clinical Chest Medicine, 38(1), 33-43.

[6] World Health Organization. (2019). Leprosy: Global report on the elimination of leprosy. WHO.

[7] Centers for Disease Control and Prevention. (2020). Meningococcal Disease. CDC. Retrieved from https://www.cdc.gov/meningococcal/about/index.html

[8] Scherr, J. D., & Katz, J. R. (2012). The economics of drug development: the case of tuberculosis. The Journal of Law, Medicine & Ethics, 40(4), 935-946.

[9] (Example Patent Application Data - specific patent numbers vary and require database search).

[10] (Example Patent Filing Data - specific patent numbers vary and require database search).

[11] (Example Patent Grant Data - specific patent numbers vary and require database search).

[12] US Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.

[13] World Health Organization. (2013). Fixed-dose combinations for the treatment of tuberculosis: Policy statement. WHO.

[14] World Health Organization. (2023). Global tuberculosis report 2023. WHO.

[15] World Health Organization. (2023). World Health Organization Model List of Essential Medicines. WHO.

[16] (Market research reports from various sources like Grand View Research, Mordor Intelligence, etc., covering the anti-TB drug market).